Publications by Stein Bergan
118 publications found
Original articles
The atorvastatin metabolite pattern in muscle tissue and blood plasma is associated with statin muscle side effects in patients with coronary heart disease; An exploratory case-control study
Atheroscler Plus, 55, 31-38
DOI 10.1016/j.athplu.2024.01.001, PubMed 38293288
Validation of a novel direct method to determine reduced adherence to atorvastatin therapy
Eur Heart J Cardiovasc Pharmacother (in press)
DOI 10.1093/ehjcvp/pvae001, PubMed 38196131
Clinical performance of volumetric finger-prick sampling for the monitoring of tacrolimus, creatinine and haemoglobin in kidney transplant recipients
Br J Clin Pharmacol, 89 (12), 3690-3701
DOI 10.1111/bcp.15870, PubMed 37537150
Plasma concentration of atorvastatin metabolites correlates with low-density lipoprotein cholesterol reduction in patients with coronary heart disease
Pharmacol Res Perspect, 11 (3), e01089
DOI 10.1002/prp2.1089, PubMed 37186070
Therapeutic Drug Monitoring and Dosage Adjustments of Immunosuppressive Drugs When Combined With Nirmatrelvir/Ritonavir in Patients With COVID-19
Ther Drug Monit, 45 (2), 191-199
DOI 10.1097/FTD.0000000000001014, PubMed 35944126
Atorvastatin Metabolite Pattern in Skeletal Muscle and Blood from Patients with Coronary Heart Disease and Statin-Associated Muscle Symptoms
Clin Pharmacol Ther, 113 (4), 887-895
DOI 10.1002/cpt.2844, PubMed 36622792
Monitoring Simvastatin Adherence in Patients With Coronary Heart Disease: A Proof-of-Concept Study Based on Pharmacokinetic Measurements in Blood Plasma
Ther Drug Monit, 44 (4), 558-567
DOI 10.1097/FTD.0000000000000992, PubMed 35482468
[Estimated glomerular filtration rate as a measurement of kidney function]
Tidsskr Nor Laegeforen, 141 (1)
DOI 10.4045/tidsskr.21.0501, PubMed 35026092
Effect of atorvastatin on muscle symptoms in coronary heart disease patients with self-perceived statin muscle side effects: a randomized, double-blinded crossover trial
Eur Heart J Cardiovasc Pharmacother, 7 (6), 507-516
DOI 10.1093/ehjcvp/pvaa076, PubMed 32609361
In vitro assessments predict that CYP3A4 contributes to a greater extent than CYP3A5 to prednisolone clearance
Basic Clin Pharmacol Toxicol, 129 (6), 427-436
DOI 10.1111/bcpt.13645, PubMed 34396687
Fast and reliable quantification of busulfan in blood plasma using two-channel liquid chromatography tandem mass spectrometry: Validation of assay performance in the presence of drug formulation excipients
J Pharm Biomed Anal, 203, 114216
DOI 10.1016/j.jpba.2021.114216, PubMed 34182411
Tacrolimus Measured in Capillary Volumetric Microsamples in Pediatric Patients-A Cross-Validation Study
Ther Drug Monit, 43 (3), 371-375
DOI 10.1097/FTD.0000000000000873, PubMed 33596033
Prednisolone and Prednisone Pharmacokinetics in Adult Renal Transplant Recipients
Ther Drug Monit, 43 (2), 247-255
DOI 10.1097/FTD.0000000000000835, PubMed 33181621
Measuring Intracellular Concentrations of Calcineurin Inhibitors: Expert Consensus from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Expert Panel
Ther Drug Monit, 42 (5), 665-670
DOI 10.1097/FTD.0000000000000780, PubMed 32520841
Severe Mycophenolate Intoxication in a Solid Organ Transplant Recipient-No Intervention Actually Needed
Transplant Direct, 6 (10), e609
DOI 10.1097/TXD.0000000000001058, PubMed 33062842
Fasting Status and Circadian Variation Must be Considered When Performing AUC-based Therapeutic Drug Monitoring of Tacrolimus in Renal Transplant Recipients
Clin Transl Sci, 13 (6), 1327-1335
DOI 10.1111/cts.12833, PubMed 32652886
Tacrolimus Area Under the Concentration Versus Time Curve Monitoring, Using Home-Based Volumetric Absorptive Capillary Microsampling
Ther Drug Monit, 42 (3), 407-414
DOI 10.1097/FTD.0000000000000697, PubMed 31479042
Pharmacodynamic assessment of mycophenolic acid in resting and activated target cell population during the first year after renal transplantation
Br J Clin Pharmacol, 86 (6), 1100-1112
DOI 10.1111/bcp.14218, PubMed 31925806
Measured GFR by Utilizing Population Pharmacokinetic Methods to Determine Iohexol Clearance
Kidney Int Rep, 5 (2), 189-198
DOI 10.1016/j.ekir.2019.11.012, PubMed 32043033
Cardiovascular rEmodelling in living kidNey donorS with reduced glomerular filtration rate: rationale and design of the CENS study
Blood Press, 29 (2), 123-134
DOI 10.1080/08037051.2019.1684817, PubMed 31718316
A novel direct method to determine adherence to atorvastatin therapy in patients with coronary heart disease
Br J Clin Pharmacol, 85 (12), 2878-2885
DOI 10.1111/bcp.14122, PubMed 31495943
Tacrolimus Can Be Reliably Measured With Volumetric Absorptive Capillary Microsampling Throughout the Dose Interval in Renal Transplant Recipients
Ther Drug Monit, 41 (5), 607-614
DOI 10.1097/FTD.0000000000000655, PubMed 31584926
Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report
Ther Drug Monit, 41 (3), 261-307
DOI 10.1097/FTD.0000000000000640, PubMed 31045868
Statin-associated muscle symptoms in coronary patients: design of a randomized study
Scand Cardiovasc J, 53 (3), 162-168
DOI 10.1080/14017431.2019.1612085, PubMed 31030568
Pharmacogenetics in personalised drug therapy
Tidsskr Nor Laegeforen, 139 (8)
DOI 10.4045/tidsskr.19.0055, PubMed 31062549
A Method for Direct Monitoring of Atorvastatin Adherence in Cardiovascular Disease Prevention: Quantification of the Total Exposure to Parent Drug and Major Metabolites Using 2-Channel Chromatography and Tandem Mass Spectrometry
Ther Drug Monit, 41 (1), 19-28
DOI 10.1097/FTD.0000000000000578, PubMed 30633723
A Fully Automated Method for the Determination of Serum Belatacept and Its Application in a Pharmacokinetic Investigation in Renal Transplant Recipients
Ther Drug Monit, 41 (1), 11-18
DOI 10.1097/FTD.0000000000000580, PubMed 30633722
Longitudinal Study of Tacrolimus in Lymphocytes During the First Year After Kidney Transplantation
Ther Drug Monit, 40 (5), 558-566
DOI 10.1097/FTD.0000000000000539, PubMed 30086087
Effects of marine n-3 fatty acid supplementation in renal transplantation: A randomized controlled trial
Am J Transplant, 19 (3), 790-800
DOI 10.1111/ajt.15080, PubMed 30125457
Estimated glomerular filtration rate in stable older kidney transplant recipients-are present algorithms valid? A national cross-sectional cohort study
Transpl Int, 31 (6), 629-638
DOI 10.1111/tri.13137, PubMed 29453878
Estimating Glomerular Filtration Rate in Kidney Transplant Recipients: Comparing a Novel Equation With Commonly Used Equations in this Population
Transplant Direct, 3 (12), e332
DOI 10.1097/TXD.0000000000000742, PubMed 29536033
Prednisolone and Prednisone Pharmacokinetics in Pediatric Renal Transplant Recipients-A Prospective Study
Ther Drug Monit, 39 (5), 472-482
DOI 10.1097/FTD.0000000000000439, PubMed 28749817
NFAT-regulated cytokine gene expression during tacrolimus therapy early after renal transplantation
Br J Clin Pharmacol, 83 (11), 2494-2502
DOI 10.1111/bcp.13367, PubMed 28686294
High Tacrolimus Clearance Is a Risk Factor for Acute Rejection in the Early Phase After Renal Transplantation
Transplantation, 101 (8), e273-e279
DOI 10.1097/TP.0000000000001796, PubMed 28452920
Defect related radiative recombination in mono-like crystalline silicon wafers
Phys. Status Solidi A-Appl. Mat., 214 (8), 1700124
DOI 10.1002/pssa.201700124
Exposure to Mycophenolate and Fatherhood
Transplantation, 101 (7), e214-e217
DOI 10.1097/TP.0000000000001747, PubMed 28346297
The CYP3A biomarker 4β-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation
Br J Clin Pharmacol, 83 (7), 1457-1465
DOI 10.1111/bcp.13248, PubMed 28146606
Low-target tacrolimus in de novo standard risk renal transplant recipients: A single-centre experience
Nephrology (Carlton), 21 (10), 821-7
DOI 10.1111/nep.12738, PubMed 26854648
Prediction of Fat-Free Mass in Kidney Transplant Recipients
Ther Drug Monit, 38 (4), 439-46
DOI 10.1097/FTD.0000000000000305, PubMed 27019101
Treatment with Tacrolimus and Sirolimus Reveals No Additional Adverse Effects on Human Islets In Vitro Compared to Each Drug Alone but They Are Reduced by Adding Glucocorticoids
J Diabetes Res, 2016, 4196460
DOI 10.1155/2016/4196460, PubMed 26885529
Drug target molecules to guide immunosuppression
Clin Biochem, 49 (4-5), 411-8
DOI 10.1016/j.clinbiochem.2015.10.001, PubMed 26453533
Improved Tacrolimus Target Concentration Achievement Using Computerized Dosing in Renal Transplant Recipients--A Prospective, Randomized Study
Transplantation, 99 (10), 2158-66
DOI 10.1097/TP.0000000000000708, PubMed 25886918
Glutathione Transferase Gene Variants Influence Busulfan Pharmacokinetics and Outcome After Myeloablative Conditioning
Ther Drug Monit, 37 (4), 493-500
DOI 10.1097/FTD.0000000000000180, PubMed 25565670
Pharmacist assessment of drug-related problems on an oncology ward
Eur. J. Hosp. Pharm., 22 (4), 194-197
DOI 10.1136/ejhpharm-2014-000510
Intracellular sirolimus concentration is reduced by tacrolimus in human pancreatic islets in vitro
Transpl Int, 28 (10), 1152-61
DOI 10.1111/tri.12617, PubMed 26046470
Use of generic tacrolimus in elderly renal transplant recipients: precaution is needed
Transplantation, 99 (3), 528-32
DOI 10.1097/TP.0000000000000384, PubMed 25148382
Glomerular filtration rate measured by iohexol clearance: A comparison of venous samples and capillary blood spots
Scand J Clin Lab Invest, 75 (8), 710-6
DOI 10.3109/00365513.2015.1091091, PubMed 26426851
[Allogeneic stem-cell transplantation in adults 1985-2012: results and development]
Tidsskr Nor Laegeforen, 134 (16), 1569-75
DOI 10.4045/tidsskr.13.1415, PubMed 25178233
Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling
Br J Clin Pharmacol, 78 (3), 509-23
DOI 10.1111/bcp.12361, PubMed 25279405
The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients
Eur J Clin Pharmacol, 70 (6), 685-93
DOI 10.1007/s00228-014-1656-3, PubMed 24658827
Simultaneous quantification of IMPDH activity and purine bases in lymphocytes using LC-MS/MS: assessment of biomarker responses to mycophenolic acid
Ther Drug Monit, 36 (1), 108-18
DOI 10.1097/FTD.0b013e3182a13900, PubMed 24061448
Tacrolimus exposure and mycophenolate pharmacokinetics and pharmacodynamics early after liver transplantation
Ther Drug Monit, 36 (1), 46-53
DOI 10.1097/FTD.0b013e31829dcb66, PubMed 24081206
Pharmacogenetically based dosing of thiopurines in childhood acute lymphoblastic leukemia: influence on cure rates and risk of second cancer
Pediatr Blood Cancer, 61 (5), 797-802
DOI 10.1002/pbc.24921, PubMed 24395436
Inclusion of CYP3A5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation
Transpl Int, 26 (12), 1198-207
DOI 10.1111/tri.12194, PubMed 24118301
Importance of hematocrit for a tacrolimus target concentration strategy
Eur J Clin Pharmacol, 70 (1), 65-77
DOI 10.1007/s00228-013-1584-7, PubMed 24071959
A taste of individualized medicine: physicians' reactions to automated genetic interpretations
J Am Med Inform Assoc, 21 (e1), e143-6
DOI 10.1136/amiajnl-2012-001587, PubMed 24001515
Mycophenolate pharmacokinetics and inosine monophosphate dehydrogenase activity in liver transplant recipients with an emphasis on therapeutic drug monitoring
Scand J Clin Lab Invest, 73 (2), 117-24
DOI 10.3109/00365513.2012.745947, PubMed 23281843
The pharmacokinetics of prednisolone and prednisone in adult liver transplant recipients early after transplantation
Ther Drug Monit, 34 (4), 452-9
DOI 10.1097/FTD.0b013e31825ee3f8, PubMed 22777155
Quantification of 6 glucocorticoids in human plasma by liquid chromatography tandem mass spectrometry: method development, validation, and assessment of matrix effects
Ther Drug Monit, 33 (4), 402-10
DOI 10.1097/FTD.0b013e3182241799, PubMed 21743383
No change in insulin sensitivity in renal transplant recipients converted from standard to once-daily prolonged release tacrolimus
Nephrol Dial Transplant, 26 (11), 3767-72
DOI 10.1093/ndt/gfr153, PubMed 21471328
Determination of cyclosporine, tacrolimus, sirolimus and everolimus by liquid chromatography coupled to electrospray ionization and tandem mass spectrometry: assessment of matrix effects and assay performance
Scand J Clin Lab Invest, 70 (8), 583-91
DOI 10.3109/00365513.2010.531141, PubMed 21039189
Cyclosporine C2 levels have impact on incidence of rejection in de novo lung but not heart transplant recipients: the NOCTURNE study
J Heart Lung Transplant, 28 (9), 919-26
DOI 10.1016/j.healun.2009.05.022, PubMed 19716045
Determination of digoxin and digitoxin in whole blood
J Anal Toxicol, 33 (7), 372-8
DOI 10.1093/jat/33.7.372, PubMed 19796507
Mycophenolate pharmacokinetics and pharmacodynamics in belatacept treated renal allograft recipients - a pilot study
J Transl Med, 7, 64
DOI 10.1186/1479-5876-7-64, PubMed 19635156
Rimonabant affects cyclosporine a, but not tacrolimus pharmacokinetics in renal transplant recipients
Transplantation, 87 (8), 1221-4
DOI 10.1097/TP.0b013e31819f1001, PubMed 19384170
Pharmacodynamics of mycophenolic acid in CD4+ cells: a single-dose study of IMPDH and purine nucleotide responses in healthy individuals
Ther Drug Monit, 30 (6), 647-55
DOI 10.1097/FTD.0b013e31818955c3, PubMed 18806697
Reduced elimination of cyclosporine A in elderly (>65 years) kidney transplant recipients
Transplantation, 86 (10), 1379-83
DOI 10.1097/TP.0b013e31818aa4b6, PubMed 19034006
Expression of IMPDH1 is regulated in response to mycophenolate concentration
Int Immunopharmacol, 9 (2), 173-80
DOI 10.1016/j.intimp.2008.10.017, PubMed 19010451
Oral anticoagulation with warfarin is significantly influenced by steroids and CYP2C9 polymorphisms in children with cancer
Pediatr Blood Cancer, 50 (3), 710-3
DOI 10.1002/pbc.21133, PubMed 17226852
Expression of IMPDH1 and IMPDH2 after transplantation and initiation of immunosuppression
Transplantation, 85 (1), 55-61
DOI 10.1097/01.tp.0000296854.68123.03, PubMed 18192912
IMP dehydrogenase basal activity in MOLT-4 human leukaemia cells is altered by mycophenolic acid and 6-thioguanosine
Scand J Clin Lab Invest, 68 (4), 277-85
DOI 10.1080/00365510701724871, PubMed 18609073
Cinacalcet's effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients
Nephrol Dial Transplant, 23 (3), 1048-53
DOI 10.1093/ndt/gfm632, PubMed 17956893
Real-time PCR determination of IMPDH1 and IMPDH2 expression in blood cells
Clin Chem, 53 (6), 1023-9
DOI 10.1373/clinchem.2006.081968, PubMed 17463174
Determination of inosine monophosphate dehydrogenase activity in human CD4+ cells isolated from whole blood during mycophenolic acid therapy
Ther Drug Monit, 28 (5), 608-13
DOI 10.1097/01.ftd.0000245680.38143.ca, PubMed 17038874
Calcineurin inhibitor-free immunosuppression in renal allograft recipients with thrombotic microangiopathy/hemolytic uremic syndrome
Am J Transplant, 6 (2), 412-8
DOI 10.1111/j.1600-6143.2005.01184.x, PubMed 16426329
Mycophenolic acid clinical pharmacokinetics influenced by a cyclosporine C2 based immunosuppressive regimen in renal allograft recipients
Transpl Int, 19 (1), 44-53
DOI 10.1111/j.1432-2277.2005.00228.x, PubMed 16359376
Inosine monophosphate dehydrogenase activity in renal allograft recipients during mycophenolate treatment
Scand J Clin Lab Invest, 66 (1), 31-44
DOI 10.1080/00365510500420259, PubMed 16464785
C2 monitoring in maintenance renal transplant recipients: is it worthwhile?
Transplantation, 76 (8), 1236-8
DOI 10.1097/01.TP.0000085046.39523.D5, PubMed 14578761
Automated determination of free mycophenolic acid and its glucuronide in plasma from renal allograft recipients
Ther Drug Monit, 25 (3), 407-14
DOI 10.1097/00007691-200306000-00025, PubMed 12766573
Pharmacokinetics of diltiazem and its metabolites in relation to CYP2D6 genotype
Clin Pharmacol Ther, 72 (3), 333-42
DOI 10.1067/mcp.2002.127396, PubMed 12235455
Effects of DDT on paracetamol half-life in highly exposed mothers in Zimbabwe
Toxicol Lett, 134 (1-3), 147-53
DOI 10.1016/s0378-4274(02)00184-4, PubMed 12191873
Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients
Am J Transplant, 1 (4), 382-6
DOI 10.1034/j.1600-6143.2001.10415.x, PubMed 12099384
Glipizide treatment of post-transplant diabetes does not interfere with cyclosporine pharmacokinetics in renal allograft recipients
Clin Transplant, 12 (6), 553-6
PubMed 9850449
Monitored high-dose azathioprine treatment reduces acute rejection episodes after renal transplantation
Transplantation, 66 (3), 334-9
DOI 10.1097/00007890-199808150-00010, PubMed 9721802
Analysis of methylated 6-mercaptopurine metabolites in human red blood cells: comparison of two methods
Ther Drug Monit, 19 (6), 663-8
DOI 10.1097/00007691-199712000-00010, PubMed 9421108
Optimisation of azathioprine immunosuppression after organ transplantation by pharmacological measurements
BioDrugs, 8 (6), 446-56
DOI 10.2165/00063030-199708060-00005, PubMed 18031107
Patterns of azathioprine metabolites in neutrophils, lymphocytes, reticulocytes, and erythrocytes: relevance to toxicity and monitoring in recipients of renal allografts
Ther Drug Monit, 19 (5), 502-9
DOI 10.1097/00007691-199710000-00003, PubMed 9357091
Possibilities for therapeutic drug monitoring of azathioprine: 6-thioguanine nucleotide concentrations and thiopurine methyltransferase activity in red blood cells
Ther Drug Monit, 19 (3), 318-26
DOI 10.1097/00007691-199706000-00013, PubMed 9200774
Optimization of azathioprine therapy by measuring 6-thioguanine nucleotides and methylated mercaptopurine in renal allograft recipients
Transplant Proc, 27 (6), 3426
PubMed 8540033
Monitoring of azathioprine treatment by determination of 6-thioguanine nucleotide concentrations in erythrocytes
Transplantation, 58 (7), 803-8
PubMed 7940715
Kinetics of mercaptopurine and thioguanine nucleotides in renal transplant recipients during azathioprine treatment
Ther Drug Monit, 16 (1), 13-20
DOI 10.1097/00007691-199402000-00002, PubMed 8160249
Cyclosporine A monitoring in patients with renal, cardiac, and liver transplants: a comparison between fluorescence polarization immunoassay and two different RIA methods
Scand J Clin Lab Invest, 53 (5), 471-7
DOI 10.1080/00365519309092542, PubMed 8210969
DIASTOLIC TIME IN PATIENTS TREATED WITH TIMOLOL OR PLACEBO AFTER ACUTE MYOCARDIAL-INFARCTION
Am. J. Noninvas. Cardiol., 7 (4), 220-224
DOI 10.1159/000470283
Lack of effect of the calcium antagonist isradipine on cyclosporine pharmacokinetics in renal transplant patients
Ther Drug Monit, 13 (6), 490-5
DOI 10.1097/00007691-199111000-00004, PubMed 1837629
[Side effects of antitubercular drugs leading to discontinuation of drug therapy]
Tidsskr Nor Laegeforen, 100 (5), 279-82
PubMed 7385151
Review articles
Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology
Ther Drug Monit, 43 (2), 150-200
DOI 10.1097/FTD.0000000000000871, PubMed 33711005
Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drug-Drug Interactions
Ther Drug Monit, 42 (3), 360-368
DOI 10.1097/FTD.0000000000000761, PubMed 32304488
Barcelona Consensus on Biomarker-Based Immunosuppressive Drugs Management in Solid Organ Transplantation
Ther Drug Monit, 38 Suppl 1, S1-20
DOI 10.1097/FTD.0000000000000287, PubMed 26977997
Pharmacogenetic Biomarkers Predictive of the Pharmacokinetics and Pharmacodynamics of Immunosuppressive Drugs
Ther Drug Monit, 38 Suppl 1, S57-69
DOI 10.1097/FTD.0000000000000255, PubMed 26469711
Therapeutic Drug Monitoring of Belatacept in Kidney Transplantation
Ther Drug Monit, 37 (5), 560-7
DOI 10.1097/FTD.0000000000000179, PubMed 25551406
[Immunosuppressive drugs and the development of skin cancer after organ transplantation]
Tidsskr Nor Laegeforen, 132 (18), 2064-8
DOI 10.4045/tidsskr.12.0389, PubMed 23038197
[Drug interactions and immunosuppression in organ transplant recipients]
Tidsskr Nor Laegeforen, 131 (20), 2000-3
DOI 10.4045/tidsskr.11.0138, PubMed 22016125
[Individualized pharmacotherapy based on cytochrome P-450 (CYP) genotyping]
Tidsskr Nor Laegeforen, 122 (29), 2781-3
PubMed 12523145
[Immunosuppressive agents in organ transplantation]
Tidsskr Nor Laegeforen, 119 (24), 3615-20
PubMed 10563181
[Mycophenolate mofetil--a new immunosuppressive agent]
Tidsskr Nor Laegeforen, 116 (20), 2439-41
PubMed 8928103
Other articles
Therapeutic Drug Monitoring in the Era of Precision Medicine: Achievements, Gaps, and Perspectives-An Interview in Honor of Professor Charles Pippenger
Ther Drug Monit, 43 (6), 719-727
DOI 10.1097/FTD.0000000000000932, PubMed 34654029
Pharmacogenetics in personalised drug therapy
Tidsskr. Nor. Laegeforen., 139 (8), 700-702
The Authors' Reply
Transplantation, 102 (1), e43-e44
DOI 10.1097/TP.0000000000001961, PubMed 28957846
Costimulation Blockade: America First, Canada Second … What About Norway?
Am J Transplant, 17 (8), 2230
DOI 10.1111/ajt.14351, PubMed 28508535
Response to: 'Response to: Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance'
Br J Clin Pharmacol, 83 (6), 1357-1358
DOI 10.1111/bcp.13276, PubMed 28374426
Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance
Br J Clin Pharmacol, 83 (6), 1350-1352
DOI 10.1111/bcp.13188, PubMed 28008657
Pharmacology Portal: An Open Database for Clinical Pharmacologic Laboratory Services
Clin Ther, 38 (1), 222-6
DOI 10.1016/j.clinthera.2015.10.015, PubMed 26546404
[Customized drugs?]
Tidsskr Nor Laegeforen, 126 (18), 2364
PubMed 16998544
TDM: report concentration, Css, rather than area under the curve, AUC
Ther Drug Monit, 25 (6), 743
DOI 10.1097/00007691-200312000-00015, PubMed 14639063
[Better therapeutic potential for azathioprine and mercaptopurine]
Lakartidningen, 97 (16), 1999-2000
PubMed 10826362
Books
Materialadministrasjon og kapitalrasjonalisering
In Temahefte, ISI, Oslo, 7, 7 s.
BIBSYS 930568982
Theses
Azathioprine monitoring in renal transplantation
Department of Clinical Pharmacology, Institute of Clinical Biochemistry, Department of Surgery, University of Oslo, Rikshospitalet, [Oslo], 1 b. (flere pag.)
BIBSYS 982283202, ISBN 82-7633-106-8
Bivirkninger av tuberkulostatika
S. Bergan, Oslo, 87 s.
BIBSYS 961713232